Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces superior glycemic control and weight loss compared to other current pharmacotherapies for type 2 diabetes.
Tirzepatide is a once-weekly injection that helps lower blood sugar and lose weight more effectively than many current diabetes drugs. It works by mimicking hormones that regulate insulin and appetite. While nausea is a common side effect, most people tolerate it well, and only a small percentage stop taking it. It is particularly useful for those who struggle with weight gain from other diabetes medications.
Tirzepatida é o único fármaco atualmente disponível que combina a ação nas incretinas GLP-1 e GIP em uma única injeção, e sua eficácia na redução dos níveis de açúcar no sangue e na perda de peso é superior a outros tratamentos atualmente usados.
Why this rating
Based on multiple Phase 3 randomized controlled trials (SURPASS-1, 2, 3, 4, 5; SURMOUNT-1) cited in the review.
Source
TIRZEPATIDA - UMA NOVA FARMACOTERAPIA PARA DIABETES MELITTUS TIPO 2
Lívia Beatriz Almeida Fontes et al. · Revista Científica Fagoc. · 2024
DOI 10.61224/2525-5045.2023.1097
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →